Early Value Assessments are not shortcuts to reimbursement. They are tests of whether a technology deserves the NHS’s attention while uncertainty is still unresolved. In recent years, NICE has been …

What Medicare’s DMHT Codes Signal for Digital Therapeutics Reimbursement and Why Healthcare Is Paying Attention Digital therapeutics reimbursement refers to how public and private healthcare systems pay for evidence-based software …

France 2030 medical device funding is a major public investment opportunity for teams developing implantable medical devices and next-generation surgical robotics. Managed via Bpifrance under the France 2030 investment plan, …

How Reimbursement Actually Works in Poland This paper explains how reimbursement in Poland actually works for MedTech, IVD, digital health, and AI technologies — including the role of NFZ, DRGs …

Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct  but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are …

How the New Coding and Payment Model Is Reshaping Hospital Care and Which Technologies Fit It Best For 2026, the German Hybrid-DRG system underwent a significant expansion, increasing to 69 …